Portal de Periódicos da CAPES

Neurochemical Responses to 6‐Hydroxydopamine and L‐Dopa Therapy: Implications for Parkinson's Disease a

1992; Wiley; Volume: 648; Issue: 1 Linguagem: Inglês

10.1111/j.1749-6632.1992.tb24525.x

1749-6632

Michael J. Zigmond, Teresa G. Hastings, Elizabeth D. Abercrombie,

Neurological disorders and treatments

Annals of the New York Academy of SciencesVolume 648, Issue 1 p. 71-86 Neurochemical Responses to 6-Hydroxydopamine and L-Dopa Therapy: Implications for Parkinson's Diseasea MICHAEL J. ZIGMOND, MICHAEL J. ZIGMOND Department of Behavioral Neuroscience University of Pittsburgh Pittsburgh, Pennsylvania 15260Search for more papers by this authorTERESA G. HASTINGS, TERESA G. HASTINGS Department of Behavioral Neuroscience University of Pittsburgh Pittsburgh, Pennsylvania 15260Search for more papers by this authorELIZABETH D. ABERCROMBIE, ELIZABETH D. ABERCROMBIE Center for Molecular and Behavioral Neuroscience Rutgers University Newark, New Jersey 07102Search for more papers by this author MICHAEL J. ZIGMOND, MICHAEL J. ZIGMOND Department of Behavioral Neuroscience University of Pittsburgh Pittsburgh, Pennsylvania 15260Search for more papers by this authorTERESA G. HASTINGS, TERESA G. HASTINGS Department of Behavioral Neuroscience University of Pittsburgh Pittsburgh, Pennsylvania 15260Search for more papers by this authorELIZABETH D. ABERCROMBIE, ELIZABETH D. ABERCROMBIE Center for Molecular and Behavioral Neuroscience Rutgers University Newark, New Jersey 07102Search for more papers by this author First published: May 1992 https://doi.org/10.1111/j.1749-6632.1992.tb24525.xCitations: 57 a This work was supported in part by USPHS Grants NS-19608, MH-00058, MH-18273, and MH-30915, and by the American Parkinson's Disease Association. AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat REFERENCES 1 Senoh, S., C. R. Creveling, S. Udenfriend & B. Witkop. 1959. Chemical, enzymatic and metabolic studies on the mechanism of oxidation of dopamine. J. Am. Chem. Soc. 81: 6236–6240. 2 Porter, C. C., J. A. Totaro & C. A. Stone. 1963. Effect of 6-hydroxydopamine and some other compounds on the concentration of norepinephrine in the hearts of mice. J. Pharmacol. Exp. Ther. 140: 308. 3 Thoenen, H. & P. Tranzer. 1968. Chemical sympathectomy by selective destruction of adrenergic nerve endings with 6-hydroxydopamine. Naunyn-Schmiedeberg's Arch. Pharmakol. Exp. Pathol. 261: 271–288. 4 Consolo, S., S. Garattini, H. Ladinsky & H. Thoenen. 1972. Effect of chemical sympathectomy on the content of acetylcholine, choline and choline acetyltransferase activity in the cat spleen and iris. J. Physiol. 220: 639–646. 5 Jonsson, G. & C. Sachs. 1970. Effects of 6-hydroxydopamine on the uptake and storage of noradrenaline in sympathetic adrenergic neurons. Eur. J. Pharmacol. 9: 141–155. 6 Thoenen, H. & J. P. Tranzer. 1973. The pharmacology of 6-hydroxydopamine. Annu. Rev. Pharmacol. 13: 169–180. 7 Laverty, R., D. Sharman & M. Vogt. 1965. Action of 2,4,5-trihydroxyphenethylamine on the storage and release of noradrenaline. Br. J. Pharmacol. 24: 549–560. 8 Ungerstedt, U. 1968. 6-Hydroxydopamine induced degeneration of central monoamine neurons. Eur. J. Pharmacol. 5: 107–110. 9 Breese, G. R. & T. D. Traylor. 1970. Effects of 6-hydroxydopamine on brain norepinephrine and dopamine: Evidence of selective degeneration of catecholamine neurons. J. Pharmacol. Exp. Ther. 174: 413–420. 10 Bloom, F. E., S. Algeria, A. Groppetti, A. Revuelta & E. Costa. 1969. Lesions of central norepinephrine terminals with 6-hydroxydopamine: Biochemistry and fine structure. Science. 166: 1284–1286. 11 Iversen, L. L. & N. J. Uretsky. 1970. Regional effects of 6-hydroxydopamine on catecholamine containing neurones in rat brain and spinal cord. Brain Res. 24: 364–367. 12 Uretsky, N. J. & L. L. Iversen. 1970. Effects of 6-hydroxydopamine on catecholamine containing neurones in rat brain. J. Neurochem. 17: 269–278. 13 Hedreen, J. C. & J. P. Chalmers. 1972. Neuronal degeneration in rat brain induced by 6-hydroxydopamine: A histological and biochemical study. Brain Res. 47: 1–36. 14 Agid, Y., F. Javoy, J. Glowinski, D. Bouvet & C. Sotelo. 1973. Injection of 6-hydroxydopamine into the substantia nigra of the rat. II. Diffusion and specificity. Brain Res. 58: 291–301. 15 Jacks, B. R., J. De Champlain & J. P. Cordeau. 1972. Effects of 6-hydroxydopamine on putative transmitter substances in the central nervous system. Eur. J. Pharmacol. 18: 353–360. 16 Kim, J. S. 1973. Effects of 6-hydroxydopamine on acetylcholine and GABA metabolism in rat striatum. Brain Res. 55: 472–475. 17 Breese, G. R. 1975. Chemical and immunochemical lesions by specific neurotoxic substances and antisera. In Handbook of Psychopharmacology: Biochemical Principles and Techniques in Neuropharmacology. L. L. Iversen, S. D. Iversen & S. H. Snyder, eds. Vol. I: 137–189. Plenum Press. New York . 18 Jonsson, G. 1980. Chemical neurotoxins as denervation tools in neurobiology. Annu. Rev. Neurosci. 3: 169–187. 19 Kostrzewa, R. M. & D. M. Jacobowitz. 1974. Pharmacological action of 6-hydroxydopamine. Pharmacol. Rev. 26: 199–288. 20 Zigmond, M. J. & E. M. Stricker. 1989. Animal Models of Parkinsonism Using Selective Neurotoxins: Clinical and Basic Implications. In International Review of Neurobiology. R. J. Bradley, ed. Vol. 31: 1–79. Academic Press. New York . 21 Heikkila, R. & G. Cohen. 1972. Further studies on the generation of hydrogen peroxide by 6-hydroxydopamine: Potentiation by ascorbic acid. Mol. Pharmacol. 8: 241–248. 22 Sachs, C. H. & G. Jonsson. 1975. Mechanisms of action of 6-hydroxydopamine. Pharmacology 24: 1–8. 23 Zigmond, M. J., E. D. Abercrombie, T. W. Berger, A. A. Grace & E. M. Stricker. 1990. Compensations after lesions of central dopaminergic neurons: Some clinical and basic implications. Trends Neurosci. 13: 290–296. 24 Breese, G. R. & J. L. Howard. 1971. Effect of central catecholamine alterations on the hypothalamic response to 6-hydroxydopamine in desipramine-treated rats. Br. J. Pharmacol. 43: 671–674. 25 De Champlain, J. 1971. Degeneration and regrowth of adrenergic nerve fibers in the rat peripheral tissues after 6-hydroxydopamine. Can. J. Physiol. Pharmacol. 49: 345–355. 26 Onn, S. P., T. W. Berger, E. M. Stricker & M. J. Zigmond. 1986. Effects of intraventricular 6-hydroxydopamine on the dopaminergic innervation of striatum: Histochemical and neurochemical analysis. Brain Res. 376: 8–19. 27 Zigmond, M. J. & E. M. Stricker. 1972. Deficits in feeding behavior after intraventricular injection of 6-hydroxydopamine in rats. Science 177: 1211–1214. 28 Marshall, J. F. & P. Teitelbaum. 1973. A comparison of the eating in response to hypothermic and glucoprivic challenges after nigral 6-hydroxydopamine and lateral hypothalamic electrolytic lesions in rats. Brain Res. 55: 229–233. 29 Stricker, E. M. & M. J. Zigmond. 1974. Effects on homeostasis of intraventricular injection of 6-hydroxydopamine in rats. J. Comp. Physiol. Psychol. 86: 973–994. 30 Snyder, A. M., E. M. Stricker & M. J. Zigmond. 1985. Stress-induced neurological impairments in an animal model of parkinsonism. Ann. Neurol. 18: 544–551. 31 Schoenfeld, R. I. & M. J. Zigmond. 1973. Behavioral pharmacology of 6-hydroxydopamine. In Frontiers in Catecholamine Research. E. Usdin & S. Snyder, eds.: 695–700. Pergamon Press. New York . 32 Heffner, T. G., M. J. Zigmond & E. M. Stricker. 1977. Effects of dopaminergic agonists and antagonists on feeding in intact and 6-hydroxydopamine-treated rats. J. Pharmacol. Exp. Ther. 201: 386–399. 33 Ungerstedt, U. 1971. Adipsia and aphagia after 6-hydroxydopamine induced degeneration of the nigro-striatal dopamine system. Acta Physiol. Scand. Suppl. 367: 95–122. 34 Cooper, B. R., G. R. Breese, J. L. Howard & L. D. Grant. 1972. Effect of central catecholamine alterations by 6-hydroxydopamine on shuttle box avoidance acquisition. Physiol. Behav. 9: 727–731. 35 Zigmond, M. J. & E. M. Stricker. 1973. Recovery of feeding and drinking by rats after intraventricular 6-hydroxydopamine or lateral hypothalamic lesions. Science 182: 717–720. 36 Fibiger, H., A. Zis & E. McGeer. 1973. Feeding and drinking deficits after 6-hydroxydopamine administration in the rat: Similarities to the lateral hypothalamic syndrome. Brain Res. 55: 135–148. 37 Ljungberg, T. & U. Ungerstedt. 1976. Reinstatement of eating by dopamine agonists in aphagic dopamine denervated rats. Physiol. Behav. 16: 277–283. 38 Marshall, J. F., D. Levitan & E. M. Stricker. 1976. Activation-induced restoration of sensorimotor functions in rats with dopamine-depleting brain lesions. J. Comp. Physiol. Psychol. 90: 536–546. 39 Marshall, J. F., N. Berrios & S. Sawyer. 1980. Neostriatal dopamine and sensory inattention. J. Comp. Physiol. Psych. 94: 833–846. 40 Oltmans, G. A. & J. A. Harvey. 1972. LH syndrome and brain catecholamine levels after lesions of the nigrostriatal bundle. Physiol. Behav. 8: 69–78. 41 Abercrombie, E. D., A. E. Bonatz & M. J. Zigmond. 1990. Effects of L-dopa on extracellular dopamine in striatum of normal and 6-hydroxydopamine-treated rats. Brain Res. 525: 36–44. 42 Robinson, T. E. & I. Q. Whishaw. 1988. Normalization of extracellular dopamine in striatum following recovery from a partial 6-OHDA lesion of the substantia nigra: A microdialysis study in freely moving rats. Brain Res. 450: 209–244. 43 Zhang, W. Q., H. A. Tilson, K. P. Nanry, P. M. Hudson, J. S. Hong & M. K. Stachowiak. 1988. Increased dopamine release from striata of rats after unilateral nigrostriatal bundle damage. Brain Res. 461: 335–342. 44 Hollerman, J. R. & A. A. Grace. 1990. The effects of dopamine-depleting brain lesions on the electrophysiological activity of rat substantia nigra dopamine neurons. Brain Res. 533: 203–212. 45 Bernardini, G. L., S. G. Speciale & D. G. German. 1990. Increased midbrain dopaminergic cell activity following 2′CH3-MPTP-induced dopaminergic cell loss: An in vitro electrophysiological study. Brain Res. 527: 123–129. 46 Snyder, G. L., R. W. Keller, Jr. & M. J. Zigmond. 1990. Dopamine efflux from striatal slices after intracerebral 6-hydroxydopamine: Evidence for compensatory hyperactivity of residual terminals. J. Pharmacol. Exp. Ther. 253: 867–876. 47 Stachowiak, M. K., R. W. Keller, Jr., E. M. Stricker & M. J. Zigmond. 1987. Increased dopamine efflux from striatal slices during development and after nigrostriatal bundle damage. J. Neurosci. 7: 1648–1654. 48 Snyder, A. M., M. J. Zigmond & R. D. Lund. 1986. Sprouting of serotonergic afferents into striatum after dopamine depleting lesions in infant rats: A retrograde transport and immunocytochemical study. J. Comp. Neurol. 245: 274–281. 49 Hefti, F., E. Melamed & R. J. Wurtman. 1980b. Partial lesions of the dopaminergic nigrostriatal system in rat brain: Biochemical characterization. Brain Res. 195: 123–137. 50 Zigmond, M. J., A. L. Acheson, M. K. Stachowiak & E. M. Stricker. 1984. Neurochemical compensation after nigrostriatal bundle injury in an animal model of preclinical parkinsonism. Arch. Neurol. 41: 856–861. 51 Altar, C. A., M. R. Marien & J. F. Marshall. 1987. Time course of adaptations in dopamine biosynthesis, metabolism, and release following nigrostriatal lesions: Implications for behavioral recovery from brain injury. J. Neurochem. 48: 390–399. 52 Uretsky, N. J., M. A. Simmonds & L. L. Iversen. 1971. Changes in the retention and metabolism of 3H-l-norepinephrine in rat brain in vivo after 6-hydroxydopamine pretreatment. J. Pharmacol. Exp. Ther. 176: 489–496. 53 Agid, Y., F. Javoy & J. Glowinski. 1973. Hyperactivity of remaining dopaminergic neurons after partial destruction of the nigro-striatal dopaminergic system in the rat. Nature New Biol. 245: 150–151. 54 Bernheimer, H., W. Birkmayer, O. Hornykiewicz, K. Jellinger & F. Seitelberger. 1973. Brain dopamine and the syndromes of Parkinson and Huntington: Clinical, morphological and neurochemical correlations. J. Neurol. Sci. 20: 415–455. 55 Mackenzie, R. G., M. K. Stachowiak & M. J. Zigmond. 1989. Dopaminergic inhibition of striatal acetylcholine release after 6-hydroxydopamine. Eur. J. Pharmacol. 168: 43–52. 56 Orr, W. B., T. W. Gardiner, E. M. Stricker, M. J. Zigmond & T. W. Berger. 1986. Short-term effects of dopamine-depleting brain lesions on spontaneous activity of striatal neurons: Relation to local striatal dopamine levels and behavior. Brain Res. 376: 20–28. 57 Schultz, W. & U. Ungerstedt. 1978. Short-term increase and long-term reversion of striatal cell activity after degeneration of the nigrostriatal dopamine system. Exp. Brain Res. 33: 159–171. 58 Sivam, S. P., G. R. Breese, J. E. Krause, T. C. Napier, R. A. Mueller & J. S. Hong. 1987. Neonatal and adult 6-hydroxydopamine-induced lesions differentially alter tachykinin and enkephalin gene expression. J. Neurochem. 49: 1623–1633. 59 Soghomonian, J. J. & M. F. Chesselet. 1991. Lesions of the dopaminergic nigrostriatal pathway alter preprosomatostatin messenger RNA levels in the striatum, the entopeduncular nucleus and the lateral hypothalamus of the rat. Neuroscience 42: 49–59. 60 Schoenfeld, R. I. & N. J. Uretsky. 1972. Altered response to apomorphine in 6-hydroxydopamine-treated rats. Eur. J. Pharmacol. 19: 115–118. 61 Creese, I. & S. H. Snyder. 1979. Nigrostriatal lesions enhance striatal [3H]apomorphine and [3H]spiroperidol binding. Eur. J. Pharmacol. 56: 277–281. 62 Zigmond, M. J. & E. M. Stricker. 1980. Supersensitivity after intraventricular 6-hydroxydopamine: Relation to lesion dopamine depletion. Experientia 36: 436–437. 63 Bartholini, G., J. E. Blum & A. Pletscher. 1969. Dopa-induced locomotor stimulation after inhibition of extracerebral decarboxylase. J. Pharm. Pharmacol. 21: 297–301. 64 Schoenfeld, R. I. & N. J. Uretsky. 1973. Enhancement by 6-hydroxydopamine of the effects of dopa upon the motor activity of rats. J. Pharmacol. Exp. Ther. 186: 616–624. 65 Hefti, F. & E. Melamed. 1981. Dopamine release in rat striatum after administration of L-dopa as studied with in vivo electrochemistry. Brain Res. 225: 333–346. 66 Keller, R. W., Jr., W. G. Kuhr, R. M. Wightman & M. J. Zigmond. 1988. The effect of L-dopa on in vivo dopamine release from nigrostriatal bundle neurons. Brain Res. 447: 191–194. 67 Ng, K. Y., T. N. Chase, R. W. Colburn & I. J. Kopin. 1970. L-Dopa-induced release of cerebral monoamines. Science 170: 76–77. 68 Tyce, G. M. & D. K. Rorie. 1985. Effects of L-dopa and L-tyrosine on release of free and conjugated dopamine, homovanillic acid and dihydroxyphenylacetic acid from slices of rat striatum. Life Sci. 37: 2439–2448. 69 Snyder, G. L. & M. J. Zigmond. 1990. The effects of L-dopa on in vitro dopamine release from striatum. Brain Res. 508: 181–187. 70 Breese, G. R. & T. D. Traylor. 1971. Depletion of brain noradrenaline and dopamine by 6-hydroxydopamine. Brit. J. Pharmacol. 42: 88–99. 71 Lytle, L. D., O. Hurko, J. A. Romero, K. Cottman, D. Leehey & R. J. Wurtman. 1972. The effects of 6-hydroxydopamine pretreatment on the accumulation of dopa and dopamine in brain and peripheral organs following L-dopa administration. J. Neural Transm. 33: 63–72. 72 Hefti, F., E. Melamed & R. J. Wurtman. 1981. The site of dopamine formation in rat striatum after L-dopa administration. J. Pharmacol. Exp. Ther. 217: 189–197. 73 Jackson, D. & M. J. Zigmond. 1989. Dopa-induced inhibition of striatal ACh release: Increased effectiveness after 6-hydroxydopamine. Soc. Neurosci. Abstr. 15: 124. 74 Melamed, E., F. Hefti & R. J. Wurtman. 1980. Nonaminergic striatal neurons convert exogenous L-dopa to dopamine in parkinsonism. Ann. Neurol. 8: 558–563. 75 Abercrombie, E. D. & M. J. Zigmond. 1991. In vivo neurochemical analyses of exogenously administered L-dopa: Implications for treatment of Parkinson's disease. In Basal Ganglia III. G. Bernardi, M. B. Carpenter & G. DiChiara, eds. Plenum Press. New York . 76 Graham, D. G., S. M. Tiffany, W. R. Bell, Jr. & W. F. Gutknecht. 1978. Auto-oxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine, and related compounds toward C1300 neuroblastoma cells in vitro. Mol. Pharmacol. 14: 644–653. 77 Cohen, G. 1987. Oxygen radicals and Parkinson's disease. In Oxygen Radicals and Tissue Injury. B. Halliwell, ed.: 130–135. The Federation of American Societies for Experimental Biology. Bethesda , Maryland . 78 Melamed, E. 1988. Role of the nigrostriatal dopaminergic neurons in mediating the effect of exogenous L-dopa in Parkinson's disease. Mt. Sinai J. Med. 55: 35–42. 79 Fornstedt, B., E. Pileblad & A. Carlsson. 1990. In vivo autoxidation of dopamine in guinea pig striatum increases with age. J. Neurochem. 55: 655–659. 80 Wick, M. M., L. Byers & E. Frei, III. 1977. L-Dopa: Selective toxicity for melanoma cells in vitro. Science 197: 468–469. 81 Scheulen, M., P. Wollenberg, H. M. Bolt, H. Kappus & H. Remmer. 1975. Irreversible binding of dopa and dopamine metabolites to protein by rat liver microsomes. Biochem. Biophys. Res. Commun. 66: 1396–1400. 82 Weinberger, J. & G. Cohen. 1982. The differential effect of ischemia on the active uptake of dopamine, gamma-aminobutyric acid and glutamate by brain synaptosomes. J. Neurochem. 38: 963–968. 83 Hotchkiss, A. J. & J. W. Gibb. 1980. Long-term effects of multiple doses of methamphetamine on tryptophan hydroxylase and tyrosine hydroxylase activity in rat brain. J. Pharmacol. Exp. Therap. 214: 257–262. 82 Damsma, G., D. P. Boisvert, L. A. Mudrick, D. Senkstern & H. C. Fibiger. 1990. Effect of transient forebrain ischemia and pargyline on extracellular concentrations of dopamine, serotonin, and their metabolites in the rat striatum as determined by in vivo microdialysis. J. Neurochem. 54: 801–808. 85 Rollema, H., J. B. De Vries, B. H. C. Westerink, F. M. S. Van Putten & A. S. Horn. 1986. Failure to detect 6-hydroxydopamine in rat striatum after the dopamine-releasing drugs dexamphetamine, methylamphetamine and MPTP. Eur. J. Pharmacol. 132: 65–69. 86 Schmidt, C. J., J. K. Ritter, P. K. Sonsalla, G. R. Hanson & J. W. Gibb. 1985. Role of dopamine in the neurotoxic effects of methamphetamine. J. Pharmacol. Exp. Ther. 233: 539–544. 87 Weinberger, J., J. Nieves-Rosa & G. Cohen. 1985. Nerve terminal damage in cerebral ischemia: Protective effect of alpha-methyl-para-tyrosine. Stroke 16: 864–870. 88 Sonsalla, P. K., J. W. Gibb & G. R. Hanson. 1986. Roles of D1 and D2 dopamine receptor subtypes in mediating the methamphetamine-induced changes in monoamine systems. J. Pharmacol. Exp. Ther. 238: 932–937. 89 Sonsalla, P. K., W. J. Nicklas & R. E. Heikkila. 1989. Role for excitatory amino acids in methamphetamine-induced nigrostriatal dopaminergic toxicity. Science 243: 398–400. 90 Simon, R. P., J. H. Swan, T. Griffiths & B. S. Meldrum. 1984. Blockade of N-methyl-D-aspartate receptors may protect against ischemic damage in the brain. Science 226: 850. Citing Literature Volume648, Issue1Neurotoxins and Neurodegenerative DiseaseMay 1992Pages 71-86 ReferencesRelatedInformation